Michael Smith Laboratories, Vancouver, BC, V6T 1Z4, Canada.
Future Microbiol. 2013 Jun;8(6):709-10. doi: 10.2217/fmb.13.46.
B Brett Finlay speaks to Hannah Branch, Commissioning Editor B Brett Finlay is Professor in the Michael Smith Laboratories in addition to the Departments of Microbiology and Immunology, and Biochemistry and Molecular Biology at the University of British Columbia, Canada. He received a BSc (Honors) and a PhD (1986) in biochemistry at the University of Alberta, Canada. In 1989, he started work as Assistant Professor in the Biotechnology Laboratory at the University of British Colombia. He has focused his research on host-pathogen interactions at the molecular level. He has been at the forefront of the cellular microbiology field and contributed towards a number of important discoveries in this area while publishing over 400 manuscripts. Research in his laboratory is focused on, but not restricted to, Escherichia coli and Salmonella interactions with host cells. He is known across the globe for his research and has been honored with a number of prestigious awards, including the EWR Steacie Prize, the Canadian Society of Microbiology Fisher Scientific Award, a Medical Research Council scientist award, five Howard Hughes International Research Scholar Awards, a Canadian Institute of Health Research Distinguished Investigator award, British Columbia Biotech Innovation Award, the Michael Smith Health Research Prize, the Infectious Diseases Society of America Squibb award and the Jacob Biely Prize. He is a Fellow of the Royal Society of Canada and the Canadian Academy of Health Sciences, is an Officer of the Order of Canada, and is the University of British Columbia Peter Wall Distinguished Professor. He cofounded Inimex Pharmaceuticals, Inc. (BC, Canada), and is Director of the Severe Acute Respiratory Syndrome Accelerated Vaccine Initiative. He is also a valued member of several advisory and editorial boards, including that of Future Microbiology.
B Brett Finlay 接受 Hannah Branch 的采访，B Brett Finlay 是加拿大不列颠哥伦比亚大学 Michael Smith 实验室教授，同时还在该大学的微生物学和免疫学系以及生物化学和分子生物学系任职。他在加拿大阿尔伯塔大学获得了生物化学学士（荣誉）学位和博士学位（1986 年）。1989 年，他开始在不列颠哥伦比亚大学生物技术实验室担任助理教授。他的研究重点是分子水平上的宿主-病原体相互作用。他一直处于细胞微生物学领域的前沿，在该领域做出了许多重要发现，并发表了 400 多篇论文。他的实验室的研究集中在，但不限于，大肠杆菌和沙门氏菌与宿主细胞的相互作用。他因研究而闻名全球，并获得了许多著名奖项，包括 EWR Steacie 奖、加拿大微生物学会 Fisher Scientific 奖、医学研究委员会科学家奖、五个霍华德休斯国际研究学者奖、加拿大卫生研究院杰出研究员奖、不列颠哥伦比亚省生物技术创新奖、Michael Smith 健康研究奖、传染病学会 Squibb 奖和 Jacob Biely 奖。他是加拿大皇家学会和加拿大健康科学院的研究员，是加拿大勋章的获得者，也是不列颠哥伦比亚大学 Peter Wall 杰出教授。他共同创立了 Inimex 制药公司（加拿大不列颠哥伦比亚省），并担任严重急性呼吸系统综合征加速疫苗倡议的主任。他还是Future Microbiology 等多个顾问委员会和编辑委员会的重要成员。
